Forte Biosciences Net Worth
Forte Biosciences Net Worth Breakdown | FBRX |
Forte Biosciences Net Worth Analysis
Forte Biosciences' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Forte Biosciences' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Forte Biosciences' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Forte Biosciences' net worth analysis. One common approach is to calculate Forte Biosciences' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Forte Biosciences' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Forte Biosciences' net worth. This approach calculates the present value of Forte Biosciences' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Forte Biosciences' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Forte Biosciences' net worth. This involves comparing Forte Biosciences' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Forte Biosciences' net worth relative to its peers.
Enterprise Value |
|
To determine if Forte Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Forte Biosciences' net worth research are outlined below:
| Forte Biosciences generated a negative expected return over the last 90 days | |
| Forte Biosciences has high historical volatility and very poor performance | |
| Forte Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (31.48 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Forte Biosciences currently holds about 38.55 M in cash with (28.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.89. | |
| Forte Biosciences has a frail financial position based on the latest SEC disclosures | |
| Over 80.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: One Forte Biosciences Insider Raised Stake By 273 percent In Previous Year |
Forte Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Forte Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Forte Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Forte Biosciences Target Price Consensus
Forte target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Forte Biosciences' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 2 | Strong Buy |
Most Forte analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Forte stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Forte Biosciences, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationForte Biosciences Target Price Projection
Forte Biosciences' current and average target prices are 5.71 and 3.50, respectively. The current price of Forte Biosciences is the price at which Forte Biosciences is currently trading. On the other hand, Forte Biosciences' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Forte Biosciences Market Quote on 12th of March 2025
Target Price
Analyst Consensus On Forte Biosciences Target Price
Know Forte Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Forte Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Forte Biosciences backward and forwards among themselves. Forte Biosciences' institutional investor refers to the entity that pools money to purchase Forte Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | |||
| Longwood Capital Partners Llc | 2024-12-31 | 18.1 K | |
| Geode Capital Management, Llc | 2024-12-31 | 16.9 K | |
| Blackrock Inc | 2024-12-31 | 6.8 K | |
| Royal Bank Of Canada | 2024-12-31 | 3.8 K | |
| Jpmorgan Chase & Co | 2024-12-31 | 2.1 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 151 | |
| Group One Trading, Lp | 2024-12-31 | 104 | |
| Tower Research Capital Llc | 2024-12-31 | 100.0 | |
| Comerica Bank | 2024-12-31 | 56.0 | |
| Fred Alger Management, Llc | 2024-12-31 | 1.1 M | |
| Tybourne Capital Management (hk) Ltd | 2024-12-31 | 620 K |
Follow Forte Biosciences' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 41.07 M.Market Cap |
|
Project Forte Biosciences' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.93) | (0.98) | |
| Return On Capital Employed | (0.83) | (0.87) | |
| Return On Assets | (0.93) | (0.98) | |
| Return On Equity | (0.80) | (0.84) |
When accessing Forte Biosciences' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Forte Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Forte Biosciences' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Forte Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Forte Biosciences. Check Forte Biosciences' Beneish M Score to see the likelihood of Forte Biosciences' management manipulating its earnings.
Evaluate Forte Biosciences' management efficiency
Forte Biosciences has return on total asset (ROA) of (0.6766) % which means that it has lost $0.6766 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.374) %, meaning that it created substantial loss on money invested by shareholders. Forte Biosciences' management efficiency ratios could be used to measure how well Forte Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.98 in 2025. Return On Capital Employed is likely to drop to -0.87 in 2025. At this time, Forte Biosciences' Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 831.9 K in 2025, whereas Non Current Assets Total are likely to drop slightly above 558.3 K in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 32.16 | 30.55 | |
| Tangible Book Value Per Share | 32.16 | 30.55 | |
| Enterprise Value Over EBITDA | (0.39) | (0.41) | |
| Price Book Value Ratio | 0.84 | 0.80 | |
| Enterprise Value Multiple | (0.39) | (0.41) | |
| Price Fair Value | 0.84 | 0.80 | |
| Enterprise Value | 16.1 M | 15.3 M |
The strategic initiatives led by Forte Biosciences' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Forte Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Forte Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Forte Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Forte Biosciences Corporate Filings
| 14th of February 2025 Other Reports | ViewVerify | |
| 10th of February 2025 Other Reports | ViewVerify | |
| 7th of February 2025 Other Reports | ViewVerify | |
8K | 24th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Forte Biosciences Earnings Estimation Breakdown
The calculation of Forte Biosciences' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Forte Biosciences is estimated to be -2.978325 with the future projection ranging from a low of -4.9725 to a high of -1.53. Please be aware that this consensus of annual earnings estimates for Forte Biosciences is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-4.97 Lowest | Expected EPS | -1.53 Highest |
Forte Biosciences Earnings Projection Consensus
Suppose the current estimates of Forte Biosciences' value are higher than the current market price of the Forte Biosciences stock. In this case, investors may conclude that Forte Biosciences is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Forte Biosciences' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 3 | 59.82% | -4.54 | -2.978325 | -16.38 |
Forte Biosciences Earnings per Share Projection vs Actual
Actual Earning per Share of Forte Biosciences refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Forte Biosciences predict the company's earnings will be in the future. The higher the earnings per share of Forte Biosciences, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Forte Biosciences Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Forte Biosciences, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Forte Biosciences should always be considered in relation to other companies to make a more educated investment decision.Forte Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Forte Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-11 | 2024-09-30 | -7.125 | -4.54 | 2.585 | 36 | ||
2024-08-14 | 2024-06-30 | -0.17 | -0.27 | -0.1 | 58 | ||
2024-05-13 | 2024-03-31 | -0.16 | -0.16 | 0.0 | 0 | ||
2024-03-18 | 2023-12-31 | -0.28 | -0.19 | 0.09 | 32 | ||
2023-11-13 | 2023-09-30 | -0.57 | -0.26 | 0.31 | 54 | ||
2023-03-31 | 2022-12-31 | -0.16 | -0.23 | -0.07 | 43 | ||
2022-11-14 | 2022-09-30 | -0.15 | -0.18 | -0.03 | 20 | ||
2022-08-15 | 2022-06-30 | -0.32 | -0.21 | 0.11 | 34 | ||
2022-05-16 | 2022-03-31 | -0.17 | -0.17 | 0.0 | 0 | ||
2022-03-31 | 2021-12-31 | -0.32 | -0.21 | 0.11 | 34 | ||
2021-11-08 | 2021-09-30 | -0.36 | -0.54 | -0.18 | 50 | ||
2021-08-16 | 2021-06-30 | -0.43 | -0.43 | 0.0 | 0 | ||
2021-05-10 | 2021-03-31 | -0.52 | -0.36 | 0.16 | 30 | ||
2021-03-16 | 2020-12-31 | -0.57 | -0.37 | 0.2 | 35 | ||
2020-11-09 | 2020-09-30 | -0.54 | -0.45 | 0.09 | 16 | ||
2020-08-10 | 2020-06-30 | -0.19 | -9.52 | -9.33 | 4910 | ||
2020-04-23 | 2020-03-31 | -6.6 | -6.45 | 0.15 | 2 | ||
2020-02-27 | 2019-12-31 | -8.55 | -7.5 | 1.05 | 12 | ||
2019-11-12 | 2019-09-30 | -10.49 | -11.7 | -1.21 | 11 | ||
2019-08-08 | 2019-06-30 | -11.34 | -10.8 | 0.54 | 4 | ||
2019-05-07 | 2019-03-31 | -15.15 | -11.1 | 4.05 | 26 | ||
2019-02-27 | 2018-12-31 | -10.26 | -14.4 | -4.14 | 40 | ||
2018-11-08 | 2018-09-30 | -6.75 | -0.3 | 6.45 | 95 | ||
2018-08-07 | 2018-06-30 | -8.9 | -12.15 | -3.25 | 36 | ||
2018-05-10 | 2018-03-31 | -0.57 | -9.75 | -9.18 | 1610 | ||
2018-03-08 | 2017-12-31 | -9.37 | -8.25 | 1.12 | 11 | ||
2017-11-08 | 2017-09-30 | -8.62 | -7.5 | 1.12 | 12 | ||
2017-08-09 | 2017-06-30 | -7.8 | -8.4 | -0.6 | 7 | ||
2017-05-23 | 2017-03-31 | -40.42 | -61.65 | -21.23 | 52 |
Additional Tools for Forte Stock Analysis
When running Forte Biosciences' price analysis, check to measure Forte Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Forte Biosciences is operating at the current time. Most of Forte Biosciences' value examination focuses on studying past and present price action to predict the probability of Forte Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Forte Biosciences' price. Additionally, you may evaluate how the addition of Forte Biosciences to your portfolios can decrease your overall portfolio volatility.